Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.

As to the effectiveness of anti-HER2 therapies, in the NAC setting, pCR rates were lower in IHC(2+)/FISH(+) tumors compared with IHC(3+), although the difference did not reach statistical significance.

also in 111,027 other papers